Insulet Inc. (PODD) Enterprise Value to EBITDA Ratio
Insulet Corporation (PODD) leads the tubeless pump segment, leveraging a stable cash flow from subscriptions. The company's trend EV/EBITDA level reflects a dynamic where the current metric equals 14.92. Share prices are constrained by concerns regarding the impact of GLP-1 drugs, although the unique design of Omnipod mitigates competition. However, product defect risks and logistical disruptions remain significant pressure factors.
Comprehensive metric breakdowns and analytics for insulet.com (PODD)
- current price and projected stock value:
- market capitalization details:
- business book valuation details:
- debt burden and liquidity indicators:
- financial results and valuation multiples details:
PODD - Net Financial Result|Projected Future Earnings Insulet Corporation|PODD - Price to Earnings Ratio|Forward P/E Multiple Insulet Corporation|PODD - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Insulet Inc.|PODD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Insulet|PODD - Earnings per share for the trailing year|Quarterly EPS earnings growth insulet.com|PODD - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Insulet Corporation
Analysis of all company metrics:OmniPod PODD
Insulet Corporation (PODD) is transforming diabetes therapy through its high-demand Omnipod tubeless systems, creating significant added value. By analyzing the EV/EBITDA multiple trend, an investor can see the real ratio of market capitalization plus net debt to operating profit. This coefficient neutralizes the impact of tax regimes and depreciation, allowing for an objective assessment of business efficiency. The indicator's dynamics determine the asset's investment attractiveness in the context of its debt load.
Competitor analysis
EV/EBITDA Multiple BSX (Boston Scientific Inc)|Total Company Value to Operating Income Before Depreciation Ratio Edwards Lifesciences Inc. (EW)|RMD: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio ZBH|COO: EV/EBITDA Multiple|Company Value to EBITDA Invisalign (ALGN)|GMED (Globus Medical Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation TMDX (transmedics.com)|Enterprise Value to EBITDA Ratio ATEC (Alphatec Holdings, Inc.)|AORT (artivion.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Enovis ENOV|IART - Enterprise Value to EBITDA Ratio|Motiva - EV/EBITDA Multiple|Company Value to EBITDA iLet Bionic Pancreas|IRMD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation EMBC|TNDM (Tandem Diabetes Care, Inc.) - EV/EBITDA Multiple|AxoGen Inc (AXGN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SIBN|Enterprise Value to EBITDA Ratio Orthofix Corp OFIX|EV/EBITDA Multiple BVS (Bioventus Inc.)|EV/EBITDA Multiple OrthoPediatrics Corp KIDS|TMCI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRTA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CARL (Carlsmed Corp) - Enterprise Value to EBITDA Ratio|RxSight Ophthalmic - Business Value to Operating Income Before Depreciation|CLPT (ClearPoint Neuro Inc.) - EV/EBITDA Multiple|Company Value to EBITDA stereotaxis.com STXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neuronetics (STIM)|Sight Sciences Inc. (SGHT) - Enterprise Value to EBITDA Multiple|Orchestra BioMed - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Anika Therapeutics Inc. ANIK|InspireMD, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Jin Medical International ZJYL|vivani.com (VANI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio XTNT (Xtant Medical)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroOne Corp|Enterprise Value to EBITDA Ratio Modular Med (MODD)|EV/EBITDA Multiple MYO|COCH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vivos Therapeutics, Inc. VVOS|NVNO: Enterprise Value to Operating Income Before Depreciation|SINT: Enterprise Value to EBITDA Ratio|Tenon Medical Inc - Enterprise Value to Operating Income Before Depreciation Ratio|LFWD: EV/EBITDA Multiple|AMIX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INVO Fertility|Enterprise Value to Operating Income Before Depreciation BBLG (Bone Biologics Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Axonics Modulation Technologies (AXNX)|Total Company Value to Operating Income Before Depreciation Ratio Biolase Inc.|Dynatronics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Paragon 28 Inc. FNA|INVO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
